Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



This article was originally published in The Tan Sheet

Executive Summary

Douglas Greene, MD, named to the newly created position of Exec VP-Clinical Sciences & Product Development, overseeing the research lab division's drug development process, including clinical, regulatory, biostatistics and project planning and management functions. Greene served on FDA's Endocrinologic & Metabolic Diseases Advisory Committee between 1994 and 1998, where he helped analyze the NDA for Merck's Zocor cholesterol-lowering agent. Senior VP-Clinical & Regulatory Affairs Eve Slater, MD, who oversees Merck Rx-to-OTC switches, will report to Greene. Merck is examining the switch potential of its cholesterol-lowering drug Mevacor (1see story, p. 3)

You may also be interested in...

Cholesterol Rx Drugs Reported Topic Of July NDAC Meeting

FDA may be moving toward softening its firm stance, announced in a 1997 guidance, against over-the-counter use of cholesterol-lowering drugs.

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts